At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
In Brief
A Phase 2 clinical trial evaluating Vincristine, Daunorubicin, and 8 other interventions for Precursor Cell Lymphoblastic Leukemia-Lymphoma. Currently recruiting, targeting 100 participants across 1 site.
Detailed Summary
The pediatric-inspired regimen has greatly improved the prognosis of adult patients with with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL), but relapse remains a great challenge. Venetoclax (Ven) is an oral, selective inhibitor of B-cell lymphoma 2 (Bcl-2). Although this drug is currently used primarily for acute myeloid leukemia, in vitro as well as small cohort studies suggest a effect in acute lymphoblastic leukemia. This study proposes to combine pediatric-inspired regimen with venetoclax for the treatment of adult patients with Ph- ALL, aiming to improve the MRD-negative complete remission rate measured by flow cytometry after induction and to reduce relapse, thus further improving patients overall survival.
Study Details
Timeline
Interventions
Anti-tumor alkaloids
Anthracycline
Alkylating agent
Polyethylene glycol (PEG) conjugated to L-asparaginase
Glucocorticoids
Pyrimidine antimetabolites
Cell cycle-specific antitumor drug
Glucocorticoids
Antifolate antineoplastic drug
Selective inhibitor of B-cell lymphoma 2 (Bcl-2)